**RESEARCH HIGHLIGHTS**

**Study measuring symptom burden identifies gaps in provincial program**

A Terry Fox New Investigator researching how symptom burden affects the quality of life and outcomes for adolescents and young adults diagnosed with cancer in Ontario has revealed gaps in the provincial program designed to measure these symptoms.

Project leader Dr. David Malkin discusses work of Li-Fraumeni Syndrome team

We interviewed Dr. David Malkin, who leads a research team studying the early detection and prevention of cancer in patients with Li-Fraumeni Syndrome for the past four years, to learn more about their work and impact.

**New study finds location of immune cells is critical for immunotherapy response**

New imaging technology has helped Quebec-based and funded TFRI researchers determine that the spatial distribution of immune cells within melanoma can predict how well a patient will respond to immunotherapy.

**Gut bacteria linked to immune suppression in pancreatic cancer**

TFRI-funded researchers at the University Health Network and University of Toronto have found that certain probiotic bacteria in the gut could undermine immunity in pancreatic cancer, pointing toward more personalized cancer treatments.

**Investigator finds new prognostic biomarkers in the dark matter of the cancer genome**

A new batch of prognostic cancer biomarkers in long non-coding RNAs, an area of the genome that has been largely ignored by researchers, has been discovered by a TFRI New Investigator. One of these biomarkers appears to effectively stratify risk for some patients with brain cancer.

**MOHCCN Update: From the desk of Dr. André Veillette, Executive Director, Marathon of Hope Cancer Centres Network**

Four outstanding early-career researchers will receive a total of $1.8 million as 2022 New Investigator awardees

**TFRI News: Meet our newest team members**

TFRI Events: A calendar of upcoming events in our research community